BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback